|
|
|
|
| LEADER |
01567nam a2200265 u 4500 |
| 001 |
EB002000670 |
| 003 |
EBX01000000000000001163571 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Kanga, Ismat
|
| 245 |
0 |
0 |
|a Linezolid for the treatment of infections
|h Elektronische Ressource
|b a review of the clinical and cost-effectiveness
|c Ismat Kanga, Veronica Poitras, Caitlyn Ford
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b CADTH
|c October 25, 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (60 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Poitras, Veronica
|e [author]
|
| 700 |
1 |
|
|a Ford, Caitlyn
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: peer review with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK531818
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to examine the comparative clinical effectiveness of linezolid, vancomycin and daptomycin for Methicillin-resistant Staphylococcus aureus (MRSA) infections, the comparative clinical effectiveness of linezolid and daptomycin for the treatment of VRE infections, and the cost-effectiveness of linezolid and daptomycin for MRSA and vancomycin-resistant enterococci (VRE) infections. Additionally, the clinical effectiveness and cost-effectiveness of oral versus intravenous linezolid will be examined
|